March 18th 2023
“Vanderbilt researchers are participating in numerous projects related to PRS and disease risk; studies such as this highlight the importance of evaluating whether novel clinical tools actually enhance care,” said Kerry Schaffer, MD.
February 16th 2023
January 3rd 2023
New research reveals pathways for aggressive prostate cancer subtypeDecember 8th 2022
“Our study offers molecular and cellular insights into this aggressive subtype of prostate cancer, which we hope will ultimately impact patient care,” said the study’s lead author, Hong Yuen Wong, PhD.
What can be done to raise awareness and utilization of genetic testing for prostate cancer?December 5th 2022
“Prostate cancer is…a BRCA-linked cancer, so we can increase the messaging surrounding prostate cancer on social media platforms, we can increase the amount of awareness on the genetic link that exists with prostate cancer, so that patients are also more empowered to bring this up with their providers,” says Sameer Thakker, MD.
Expert explains everything urologists need to know on genomic testingNovember 15th 2022
All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications, according to Emmanuel S. Antonarakis, MD.
Novel biomarker emerges for salvage RT approach in biochemically recurrent prostate cancerNovember 11th 2022
A higher score on PORTOS, an expression signature of 24 DNA damage repair and immune pathway genes, predicted improved response to dose-intensified salvage radiotherapy after radical prostatectomy in patients with biochemically recurrent prostate cancer.
Moffitt study shows genomic testing can identify African American prostate cancer patients with high-risk diseaseOctober 18th 2022
Moffitt Cancer Center conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer
Talazoparib/enzalutamide improves rPFS in mCRPC, regardless of HRR gene mutation statusOctober 4th 2022
The talazoparib/enzalutamide combination was also shown to have benefits in key secondary end points, including prostate specific antigen (PSA) response, time to PSA progression, and overall response rate.
Rucaparib delays disease progression in subgroup of chemotherapy-naïve mCRPCOctober 4th 2022
“Men with this type of metastatic prostate cancer want to get their genetically targeted therapy as early as possible, and this trial clearly shows the value of rucaparib as a treatment for these men,” said Alan H. Bryce, MD, principal investigator of the TRITON3 trial.
Study identifies biomarkers of enhanced nivolumab/ipilimumab efficacy in renal cell carcinomaSeptember 13th 2022
The presence of more than 2 tertiary lymphoid structures coupled with increased density of Ki-67 and PD-1 positivity was linked to an increased response rate and prolonged progression-free survival.
Maintenance rucaparib shows promise in urothelial carcinoma with DNA repair deficiencySeptember 8th 2022
In a phase 2 trial, patients with metastatic urothelial carcinoma and DNA repair deficiency who had not progressed on chemotherapy were randomized to either rucaparib maintenance or placebo.
EU OKs novel biomarker and machine learning–powered test for prostate cancerAugust 23rd 2022
The ClarityDX Prostate test assesses a combination of clinical and biological biomarker data and provides a risk score that a patient biopsy would show a clinically significant prostate cancer.
Urology Times 50 Innovations Series: Urinary molecular biomarkers in prostate cancerJuly 6th 2022
“Our ability to develop innovative technologies and approaches continues to evolve. We have newer molecular profiling techniques that are being applied to urine at the moment,” says Simpa Salami, MD, MPH.